Corporate Information — Cephalon

corporate headquarters

Cephalon, Inc.
41 Moores Road
PO Box 4011
Frazer, PA 19355
610.344.0200

investor relations

Cephalon invites stockholders, security analysts and representatives of the financial community to contact:

41 Moores Road
PO Box 4011
Frazer, PA 19355
610.883.5894

Interested parties may obtain news and information about the Company and its financial performance on the Internet at www.cephalon.com.

SEC Form 10-K

The Company’s Form 10-K as filed with the U.S. Securities and Exchange Commission is available without charge by contacting Cephalon’s Investor Relations department at 610.883.5894.

common stock listing

The common stock of Cephalon is traded on the NASDAQ Stock Market under the symbol CEPH.

transfer agent and registrar

American Stock Transfer
& Trust Company
59 Maiden Lane
New York, NY 10038
800.937.5449
www.amstock.com

annual meeting

Cephalon stockholders are invited to attend our annual meeting, which is scheduled to be held at 8:30 a.m. EDT on May 22, 2008, at Cephalon Corporate Headquarters, 41 Moores Road, Frazer, PA 19355.

independent auditors

PricewaterhouseCoopers LLP
Two Commerce Square
Suite 1700
2001 Market Street
Philadelphia, PA 19103-7042

dividends

The Company has not paid any cash dividends on the common stock since its inception and does not anticipate paying any dividends in the foreseeable future.

trademarks

Cephalon, the tagline, and the “C” logo, as well as PROVIGIL, FENTORA, EFFENTORA, ACTIQ, NUVIGIL, VIVITROL, TREANDA, TRISENOX, MYOCET, MODIODAL, SPASFON and AMRIX are trademarks or registered trademarks of Cephalon, Inc. or its subsidiaries. All other brands and names used herein are trademarks of their respective owners.

comparative stock performance graph

The graph compares the cumulative total stockholder return on the Common Stock with the cumulative total stockholder return of (i) the NASDAQ Stock Market (U.S.) Index (the “NASDAQ Index”), and (ii) the NASDAQ Pharmaceutical Stocks Total Return Index (the “Pharmaceutical Index”), assuming an investment of $100 on December 31, 2002 in each of the Common Stock of the Company; the stocks comprising the NASDAQ Index; and the stocks comprising the Pharmaceutical Index. All values assume reinvestment of the pre-tax value of dividends paid by companies included in these indices over the five-year period extending through the end of fiscal 2007.